Stock Market News2 months Pharma Stock Roundup: NVO’s Obesity Study Failure, FDA Nod to PFE, LLY Zacks
NVO’s novel obesity candidate shows lower-than-expected weight loss in the study. FDA approves LLY’s Zepbound for sleep apnea.
Eli Lilly (LLY) · Pfizer (PFE)
XNVO’s novel obesity candidate shows lower-than-expected weight loss in the study. FDA approves LLY’s Zepbound for sleep apnea.
Eli Lilly (LLY) · Pfizer (PFE)
X